Financials data is unavailable for this security.
View more
Year on year Voyager Therapeutics Inc grew revenues 511.16% from 40.91m to 250.01m while net income improved from a loss of 46.41m to a gain of 132.33m.
Gross margin | -- |
---|---|
Net profit margin | 6.28% |
Operating margin | -4.63% |
Return on assets | 2.40% |
---|---|
Return on equity | 3.38% |
Return on investment | 2.71% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Voyager Therapeutics Inc fell by 30.08m. However, the company earned 77.92m from its operations for a Cash Flow Margin of 31.17%. In addition the company generated 33.65m cash from financing while 141.64m was spent on investing.
Cash flow per share | 0.2657 |
---|---|
Price/Cash flow per share | 27.99 |
Book value per share | 6.16 |
---|---|
Tangible book value per share | 6.16 |
More ▼
Balance sheet in USDView more
Current ratio | 9.51 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼